17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
29 aug - 
Mandagens aktier: Mærsk gled til toppen efter norsk oli..
29 aug - 
Aktier/åbning: Mærsk og Novo undviger små fald ..
29 aug - 
Aktier/tendens: Godt nyt fra Nordsøen til Mærsk ..
Relateret debat
12:03 - 
Mit gak er omkring 49, så jeg så gerne at den tog nogle..
11:19 - 
Enig
10:56 - 
Har også tanket op - så meget det kunne tillades :). De..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 aug
NOVO-B
Det er en EI classic. Det burde du efterhånden have lært. Ifølge EI har alle "store" handlere skjult..
6
28 aug
NOVO-B
Du har ret hvis man købte i 1985/1988 og ikke skulle tænke på investeringen de næste 30 år, men   de..
5
26 aug
NOVO-B
Novo starter endeligt med at skære i det helt unødvendige tykke spæklag. Man starter forsigtigt ..
5
29 aug
NOVO-B
Aktierne bliver annulleret, se f.eks.:   http://www.euroinvestor.dk/nyheder/2016/04/18/novo-nordisk-..
4
28 aug
NOVO-B
På dette kursniveau Novo ligger på nu, er det en enestående mulighed for et godt køb på lang sigt. V..
4
26 aug
NOVO-B
Omkostningerne holdes måske nede, men betyder det så også at Novo vil præstere dårligere i fremtiden..
3
11:03
NOVO-B
Tilbagekøb bevirker jo at der bliver færre aktier tilbage til at dele værdien af selskabet, så aktie..
2
29 aug
NOVO-B
Novo er ikke, og har aldrig været lønførende - ihvert fald ikke i de akademiske stillinger. Det er e..
2
28 aug
NOVO-B
Normalt synes jeg du skriver nogle intelligente ting, men det råd er direkte forkert, hvis du kigger..
2
28 aug
NOVO-B
Måske tiden (og grundlaget) for Novo-aktiens fantastiske historik er ved at rinde ud?! Jeg solgte mi..
2

Fondsbørsmeddelelser

Aarsleff/CEO: Udskudte projekter øger salgsomkostningerne

30-08-2016 16:42:22
Indtjeningen i entreprenørkoncernen Aarsleff var i tredje kvartal 2015/16 presset af en stigning i salgsomkostningerne i selskabet.Og det skyldes både en svag p..

Widex/CEO: Stolt over at nå indtjeningsmål et år før tid - NY

30-08-2016 14:26:19
Den privatejede høreapparatvirksomhed Widex leverede flotte tal for både toplinjen og driften i sit årsregnskab for 2015/16, der blev præsenteret tirsdag morgen..

Vestas' gigaprojekt i USA får grønt lys af myndighederne

30-08-2016 09:52:22
Vestas' potentielle gigaordre på op til 2000 megawatt (MW) i USA er rykket et skridt nærmere.Myndighederne i staten Iowa har netop godkendt planerne for det såk..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/HSBC: Kursmålet løftes næsten 13 pct.
2
Vestas' gigaprojekt i USA får grønt lys af myndighederne
3
Mærsk: Containerrival styrtdykker på børsen i Seoul
4
Aktier/tendens: Udsigt til lav omsætning med lille pil op
5
Brøndby IF Q2: Underskuddet vokser i takt med færre på stadion

Relaterede aktiekurser

Novo Nordisk A/S 47,05 0,0% Aktiekurs uændret
Novo Nordisk B A/S 313,20 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. august 2016 19:04:08
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160826.1 - EUROWEB5 - 2016-08-30 19:04:08 - 2016-08-30 19:04:08 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x